Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5472061 | 0.82 | KDM4E (0.56) | KDM4ETSHRPOLBPKMSMN1; SMN2 | |
| SCHEMBL1008455 | 0.80 | KDM4E (0.59) | KDM4ETSHRPOLBPKMSMN1; SMN2 | |
| SCHEMBL1007625 | 0.80 | KDM4E (0.54) | KDM4ETSHRPOLBPKMSMN1; SMN2 | |
| SCHEMBL1010044 | 0.80 | KDM4E (0.54) | KDM4ETSHRPOLBPKMSMN1; SMN2 | |
| SCHEMBL6215711 | 0.80 | HSD17B10 (0.48) | — | |
| SCHEMBL20527173 | 0.79 | L3MBTL1 (0.59) | KDM4EPOLBSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6526883 | 0.79 | KDM4E (0.48) | KDM4ETSHRPOLBPKMSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL14311866 | 0.78 | KDM4E (0.52) | KDM4ETSHRPOLBPKMSMN1; SMN2 | |
| SCHEMBL11265 | 0.78 | KDM4E (0.52) | KDM4ETSHRPOLBPKMSMN1; SMN2 | |
| SCHEMBL5307853 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021062089-A1 | XANTHINE CB1 INHIBITORS | GOLDFINCH BIO, INC. (US) | 2021-04-01 | — | — | WO | claimed |
| WO-2021062089-A1 | XANTHINE CB1 INHIBITORS | GOLDFINCH BIO, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-8399667-B2 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20100152442-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB | 2010-06-17 | — | — | US | disclosed |
| EP-1565475-B1 | DIAZINOPYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080269487-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB | 2008-10-30 | — | — | US | disclosed |
| CN-100357293-C | Diazinopyrimidines | HOFFMANN LA ROCHE (CH) | 2007-12-26 | — | — | CN | disclosed |
| CN-1714093-A | Diazinopyrimidines | HOFFMANN LA ROCHE (CH) | 2005-12-28 | — | — | CN | disclosed |
| US-20050261284-A1 | Diazinopyrimidines | CHEN JIAN J | 2005-11-24 | — | — | US | disclosed |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| US-6943158-B2 | Diazinopyrimidines | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| CN-1171889-C | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase | - | 2004-10-20 | — | — | CN | disclosed |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | HOFFMANN-LA ROCHE INC. | 2004-05-20 | — | — | US | disclosed |
| CN-1382144-A | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase | HOFFMANN LA ROCHE (CH) | 2002-11-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ABL1, ERBB2, EGFR | KDM4E 2153/4885TSHR 980/4885POLB 2443/4885 |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ERBB2, ERBB4, EGFR | KDM4E 1814/4885TSHR 940/4885POLB 1916/4885 |
| US-20050261284-A1 | Diazinopyrimidines | MAPK6, MAPK1, MAP2K6 | KDM4E 4239/4885TSHR 1040/4885POLB 3111/4885 |
| US-20080269487-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ERBB2, ERBB4, EGFR | KDM4E 1814/4885TSHR 940/4885POLB 1916/4885 |
| US-20100152442-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ERBB2, ERBB4, EGFR | KDM4E 1814/4885TSHR 940/4885POLB 1916/4885 |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | FGFR1, MAPK1, FGF1 | KDM4E 4627/4885TSHR 3516/4885POLB 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.